Vyome Holdings, Inc (HIND)
$2.15-$0.06 (-2.71%) Today
Shiladitya Sengupta - Director
Venkateswarlu Nelabhotla - Officer
Robert Dickey IV - OfficerVenkateswarlu Nelabhotla - OfficerVyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
No Form 4 activity for HIND in the last 90 days.
7 Form 4 filings on record, the earliest from Aug 15, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Stanley D. Pomichter III - Director | Grant or award | Stock Option (right to buy) | 17,833 | $0.00 | - | |
| Mohanjit Jolly - Director | Grant or award | Common Stock | 454,456 | - | - | |
| John M. Tincoff III - Director | Grant or award | Stock Option (right to buy) | 17,833 | $0.00 | - | |
| Shiladitya Sengupta - Director | Grant or award | Stock Option (right to buy) | 624,432 | $0.00 | - | |
| Venkateswarlu Nelabhotla - Officer | Grant or award | Stock Option (right to buy) | 615,149 | $0.00 | - | |
| Robert Dickey IV - Officer | Grant or award | Common Stock | 762 | - | - | |
| Venkateswarlu Nelabhotla - Officer | Grant or award | Common Stock | 7 | - | - |
Vyome Holdings, Inc (HIND) has filed no insider reports in the last 90 days. The most recent on record is dated 2025-11-19. The full record for HIND runs to 7 Form 4 filings, the earliest from 2025-08-15. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of HIND were filed in the last 90 days.
No insider sales of HIND were filed in the last 90 days.
This page tracks HIND Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add HIND to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
